Loading…
← CockpitCompetitor Analysis › TNDM Tandem Diabetes Care, Inc.Open in the cockpit ↗

Tandem Diabetes Care, Inc.TNDMCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of the t:slim X2 insulin pump with Control-IQ automated dosing technology for people with diabetes.

Momentum neutral 47
Mkt cap
$1.19B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$52.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-15.1 pp
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · USD$17.05
1D-0.1%
1W-9.2%
1M+3.2%
3M-24.5%
6M+13.4%
YTD-22.4%
1Y-7.0%
ATR %8.4%
Beta1.20
52w lowhigh42.5% off high

What Tandem Diabetes Care does

Maker of the t:slim X2 insulin pump with Control-IQ automated dosing technology for people with diabetes.

Earns on the pump once, then repeatedly on disposable cartridges and infusion sets that users replace every few days, so installed users matter more than new pump sales. A growing share of orders goes through pharmacies rather than medical-equipment suppliers, and the pump connects with sensors from Dexcom and Abbott.

Products and services

  • t:slim X2 insulin pump
  • Control-IQ automated insulin dosing software
  • Mobi miniaturized insulin pump

Customers

  • Endocrinologists
  • Type 1 and insulin-using type 2 diabetes patients

Where it sits in the supply chain

  • Medical devices
  • Diabetes management technology
  • Insulin pump with automated dosing…

What could go right

  • Automated insulin delivery adoption growth
  • International market expansion

What could go wrong

  • Intense insulin-pump competition
  • Patient acquisition cost/insurance coverage dependency

Moat: narrow (IP / patents, switching costs, brand). Established Control-IQ algorithm and CGM integrations create switching costs once patients are on therapy.

Headquarters: San Diego, California · Founded: 2006 · Employees: 2,500

Named competitors

Tandem Diabetes Care at a glance

Size Tandem Diabetes Care (TNDM) is a United States Health Care company (Medical Specialties) with a market value of $1.19B, the 2126th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.05 on 18 Nov 2026.

Performance Over six months the shares gained 13.4%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 6.7% over the last twelve months (peer median +13.5%); the operating margin is -2.5% (peer median 16.0%).

Valuation It trades at 1.4× enterprise value to sales against a peer median of 4.7× (cheapest of 20).

Capital Return on invested capital runs 15.1 points below its cost of capital (10.2% WACC).

Credit Tandem Diabetes Care has 2 bonds outstanding ($616M).

Short interest Short interest is 23.2% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026TNDM 108Peer median 86
Six months, rebased to 100: Tandem Diabetes Care against the median of its 20 peers (local-currency closes).

Tandem Diabetes Care financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.07B$1.02B$940M$748M$801M
Revenue growth—+8%+26%-7%—
Gross profit$608M$531M$475M$354M$401M
EBITDA-$8.40M-$59.8M-$82.5M-$139M-$47.5M
Net income-$49.2M-$205M-$96.0M-$223M-$94.6M
Free cash flow-$36.3M-$29.7M$4.99M-$58.6M$16.4M
Capital expenditure$21.7M$19.9M$19.2M$26.8M$34.1M
Total debt$737M$449M$474M$416M$420M

Quarterly statements and history in the cockpit →

Tandem Diabetes Care competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%2675688050688161688289300406NVCRSTAADRTSATEC214150688758688198301101300595688622SIBNIRMDTNDM6-month return →1-month return →
Up and to the right = strong over both horizons. Tandem Diabetes Care is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×2675688050688161688289NVCRSTAAATEC688758688198688622TNDMRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tandem Diabetes Care is the large dot.

Tandem Diabetes Care competitors and peer comparison

Head to head with its named competitors (TNDM vs PODD vs MDT vs BBNX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Tandem Diabetes Care TNDM$1.19B+13%+7%-2%1.4×n/a
Insulet PODD$9.71B-11%+26%18%3.2×10.6%
Medtronic MDT$129B+30%+10%20%4.0×9.1%
Beta Bionics BBNX$779M+42%+44%-73%4.3×n/a
Dexcom DXCM$30.8B+16%+13%24%6.0×19.6%

How Tandem Diabetes Care compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tandem Diabetes Care against its 20 peers (data as of 18 Nov 2026)
MeasureTNDMPeer medianRank in peer set
1-month return+3.2%-7.5%7th highest of 21
6-month return+13.4%-14.3%3rd highest of 20
Distance from 52-week high-42.5%-37.5%8th lowest of 21
Revenue growth (TTM)+6.7%+13.5%7th lowest of 19
Operating margin-2.5%16.0%5th lowest of 20
EV / Sales1.4×4.7×cheapest of 20
ROIC minus cost of capital-15.1 pp+0.2 pp4th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%1.4×n/an/a
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%10.6×n/an/a
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%5.0×10.3%+40.3%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%4.7×11.3%-3.5%
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%3.8×n/an/a
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%5.8×1.7%+9.9%
NovoCure NVCRUnited States$1.25B-40%+13%-17%1.4×n/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%3.4×35.1%+7.9%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%3.3×n/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%15.4×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%13.4×20.7%+27.6%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
Ovctek China 300595.SZChina$1.33B-25%0%28%3.8×8.3%+16.5%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%

Tandem Diabetes Care bonds and credit

Tandem Diabetes Care has 2 bonds outstanding with $616M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Tandem Diabetes Care's main competitors?
Named competitors: Insulet Corporation (PODD), Medtronic (MDT), Beta Bionics (BBNX), Dexcom (DXCM). The cockpit's measured peer set (industry) also includes Shenzhen Edge Medical (2675.HK), Eyebright Medical Technology (Beijing) (688050.SS), Shandong Weigao Orthopaedic Device (688161.SS), Sansure Biotech (688289.SS), Beijing Strong Biotechnologies (300406.SZ), NovoCure (NVCR).
Is Tandem Diabetes Care expensive compared with its peers?
On ev / sales it trades at 1.4× against a peer median of 4.7×, cheapest of 20 in its peer set.
How has Tandem Diabetes Care stock performed?
Over six months to 18 Nov 2026 the shares returned +13.4% against -14.3% for the median peer; over one year -7.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.